Source: Annual Congress 2010 - Pulmonary circulation: clinical aspects
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Hsi, R. Zamanian (United States Of America). Impact of therapies on insulin resistance in pulmonary arterial hypertension. Eur Respir J 2010; 36: Suppl. 54, 5595

Member's Comments

No comment yet.

Related content which might interest you: Insulin resistance in pulmonary arterial hypertension Source: Eur Respir J 2009; 33: 318-324 Year: 2009 No indication of insulin resistance in idiopathic pulmonary arterial hypertension with preserved physical activity Source: Eur Respir J, 55 (6) 1901228; 10.1183/13993003.01228-2019 Year: 2020 Adherence to pulmonary arterial hypertension targeted therapies Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 The arterial load in pulmonary hypertension Source: Eur Respir Rev 2010 19: 197-203 Year: 2010 Assessment of simvastatin treatment on pulmonary arterial hypertension Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008 The future of treatment for pulmonary arterial hypertension Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease Year: 2018 The future of treatment for pulmonary arterial hypertension Source: School Course 2012 - Pulmonary hypertension and pulmonary vascular disease Year: 2012 The future of treatment for pulmonary arterial hypertension Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2014 The future of treatment for pulmonary arterial hypertension Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2017 The role of combination therapy in managing pulmonary arterial hypertension Source: Eur Respir Rev 2014; 23: 469-475 Year: 2014 Pulmonary vascular resistance and compliance relationship in pulmonary hypertension Source: Eur Respir J 2015; 46: 1178-1189 Year: 2015 Systemic consequences of pulmonary arterial hypertension Source: International Congress 2019 – State of the art session: Pulmonary vascular diseases Year: 2019 The effects of beta-blocker therapy on heart rate, symptoms and exercise in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Population pharmacokinetics of imatinib in patients with pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Effect of targeted therapies on survival of schistosomiasis associated pulmonary arterial hypertension Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 Exercise pathophysiology in patients with pulmonary arterial hypertension Source: Annual Congress 2007 - Mechanisms of exercise intolerance in cardiorespiratory disease Year: 2007 Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension Source: Eur Respir J 2008; 32: 393-398 Year: 2008 General and standard therapy of pulmonary arterial hypertension Source: International Congress 2017 – Russian Programme 2017 Year: 2017 Impact on survival of pulmonary function abnormalities in pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009